Press release
Cytomegalovirus (CMV) Infection Pipeline 2025: Innovative Clinical Developments by 15+ Global Leaders - DelveInsight | Featuring ModernaTX, Helocyte, VBI Vaccines, SpyBiotech, Vir Biotechnology, Glaxo
Cytomegalovirus (CMV) Infection Pipeline 2025
As Cytomegalovirus (CMV) infection continues to rise globally and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the need for safer and more effective treatments is growing. DelveInsight reports that over 15 pharmaceutical and biotech companies are actively advancing more than 20 therapeutic candidates targeting CMV infection. These candidates are in various stages of clinical and preclinical development, highlighting significant innovation and dedication to tackling this critical public health challenge.
The "Cytomegalovirus (CMV) Infection Pipeline Insight 2025" report from DelveInsight offers a comprehensive and strategic review of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and major company initiatives. This report is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving CMV therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Cytomegalovirus (CMV) Infection Drug Development @ https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Cytomegalovirus (CMV) Infection Pipeline Report
*
DelveInsight's report on the Cytomegalovirus (CMV) infection pipeline highlights a dynamic landscape, with over 15 active companies developing more than 20 therapeutic candidates for CMV treatment.
*
Prevymis (Letermovir) is an approved therapy for preventing Human Cytomegalovirus (HCMV) infection in transplant recipients, having received FDA approval in November 2017 and EMA marketing authorization in January 2018.
*
Leading companies, including ModernaTX, Helocyte, VBI Vaccines, SpyBiotech, Vir Biotechnology, GlaxoSmithKline, EVAXION BIOTECH, and others, are actively exploring novel therapies to enhance the CMV treatment landscape. Notable pipeline candidates in various stages of development include mRNA-1647, the Triplex CMV vaccine, VBI-1501, and several others.
Cytomegalovirus (CMV) Infection Overview:
Cytomegalovirus (CMV) is a common member of the herpesvirus family that usually causes asymptomatic or unnoticed infections in healthy individuals. However, in immunocompromised people, CMV can lead to serious health issues, including congenital infections, which may result in long-term complications such as hearing loss or developmental delays. Infection rates vary worldwide, and CMV is particularly adept at evading the immune system.
Following an initial infection, CMV enters a latent state within myeloid cells, remaining dormant for the host's lifetime. Although typically inactive, the virus can reactivate, posing significant risks for vulnerable populations. The immune system-especially cytotoxic T-cells-plays a key role in keeping CMV suppressed. When immunity is compromised due to factors like HIV, organ transplantation, or immunosuppressive therapy, the virus can reactivate, releasing new viral particles into the bloodstream and other body fluids, causing symptoms that range from mild to severe.
Complicating its management further, CMV has been linked to certain cancers, including mucoepidermoid carcinoma and potentially prostate cancer. Its ability to remain latent and reactivate under favorable conditions makes CMV particularly challenging to control and treat.
Download the Cytomegalovirus (CMV) Infection sample report to know in detail about the Cytomegalovirus (CMV) Infection treatment market [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Cytomegalovirus (CMV) Infection Pipeline Analysis
The Cytomegalovirus (CMV) Infection pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Cytomegalovirus (CMV) Infection Market.
*
Categorizes Cytomegalovirus (CMV) Infection therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Cytomegalovirus (CMV) Infection drugs under development based on:
*
Stage of development
*
Cytomegalovirus (CMV) Infection Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Cytomegalovirus (CMV) Infection Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Cytomegalovirus (CMV) Infection Licensing agreements
*
Funding and investment activities supporting future Cytomegalovirus (CMV) Infection market advancement.
Unlock key insights into emerging Cytomegalovirus (CMV) Infection therapies and market strategies here: https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cytomegalovirus (CMV) Infection Emerging Drugs
*
mRNA-1647: ModernaTX, Inc.
mRNA-1647 is a vaccine candidate designed to protect against Cytomegalovirus (CMV) by using six distinct messenger RNAs that encode two major viral antigens. Five of these mRNAs produce the individual components of the CMV pentameric complex, while the sixth encodes Glycoprotein B (gB)-both of which are highly immunogenic. The pentameric complex allows CMV to enter various cell types, particularly epithelial cells, whereas gB enables the virus to infect a wider range of cells, including fibroblasts.
*
Cytomegalovirus vaccine (Triplex) : Helocyte
Triplex, developed by Helocyte, is a multi-antigen vaccine engineered to elicit a robust and durable T-cell response against Cytomegalovirus (CMV), especially in patients undergoing allogeneic hematopoietic stem cell transplants (HSCT) or solid organ transplants (SOT). The vaccine employs a Modified Vaccinia Ankara (MVA) viral vector to deliver three key CMV antigens-UL83 (pp65), UL123 (IE1), and UL122 (IE2)-all of which are highly immunodominant.
Cytomegalovirus (CMV) Infection Pipeline Therapeutic Assessment
Cytomegalovirus (CMV) Infection Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Cytomegalovirus (CMV) Infection By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Cytomegalovirus (CMV) Infection Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Cytomegalovirus (CMV) Infection Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Cytomegalovirus (CMV) Infection therapies and key Cytomegalovirus (CMV) Infection companies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Cytomegalovirus (CMV) Infection Current Treatment Patterns
4. Cytomegalovirus (CMV) Infection - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cytomegalovirus (CMV) Infection Late-Stage Products (Phase-III)
7. Cytomegalovirus (CMV) Infection Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cytomegalovirus (CMV) Infection Discontinued Products
13. Cytomegalovirus (CMV) Infection Product Profiles
14. Cytomegalovirus (CMV) Infection Key Companies
15. Cytomegalovirus (CMV) Infection Key Products
16. Dormant and Discontinued Products
17. Cytomegalovirus (CMV) Infection Unmet Needs
18. Cytomegalovirus (CMV) Infection Future Perspectives
19. Cytomegalovirus (CMV) Infection Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Cytomegalovirus (CMV) Infection pipeline reports offerings [https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-cmv-infection-pipeline-2025-innovative-clinical-developments-by-15-global-leaders-delveinsight-featuring-modernatx-helocyte-vbi-vaccines-spybiotech-vir-biotechnology-glaxo]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus (CMV) Infection Pipeline 2025: Innovative Clinical Developments by 15+ Global Leaders - DelveInsight | Featuring ModernaTX, Helocyte, VBI Vaccines, SpyBiotech, Vir Biotechnology, Glaxo here
News-ID: 4229649 • Views: …
More Releases from ABNewswire
Hepatic-Colorectal Metastasis Pipeline 2025: Pioneering Clinical Developments by …
DelveInsight's, "Hepatic - Colorectal Metastasis - Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatic - Colorectal Metastasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With the prevalence of hepatic-colorectal metastasis…
Local Moving Company in Hoboken, NJ Reports Surge in Winter Bookings as Resident …
Ample Moving has experienced a notable increase in winter relocation bookings as more New Jersey residents discover the significant cost savings available during the off-peak moving season. The Jersey City-based company reports that educated consumers are increasingly choosing winter months for their relocations to take advantage of reduced rates and enhanced service availability that comes with decreased seasonal demand.
The strategic timing choice reflects growing awareness among homeowners that winter represents…
Real Estate Listing Agent in Las Vegas, NV, Forecasts Continued Inventory Growth …
LAS VEGAS, NV - Industry forecasts for the Las Vegas real estate market point toward a year of measured growth and expanding inventory, creating a balanced environment that benefits both buyers and sellers who understand the evolving dynamics. Economic projections consistently indicate price stabilization rather than dramatic increases, while housing supply continues its upward trajectory throughout the region.
Multiple industry analyses suggest that 2025 will be characterized by moderate appreciation rates…
Top Realtor in Montrose, CA, Sees Median Price Jump Despite Increased Inventory
Montrose, CA - Competitive bidding dynamics have returned to Montrose's luxury market, driving median sale prices from $1.198 million in June to an impressive $1.45 million in July, even as available inventory increased from 17 to 26 active listings. The resurgence of multiple-offer situations and accelerated closing timelines demonstrates buyer confidence in the area's long-term value proposition.
Professional staging and strategic marketing have become critical differentiators in capturing buyer attention quickly.…
More Releases for CMV
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus (CMV) Vaccine Market | Exploring Current Trends and Growth Statu …
Cytomegalovirus (CMV) Vaccine Market Outlook and Investment Analysis
What is the current outlook for the Cytomegalovirus (CMV) vaccine market?
The CMV vaccine market is seeing positive growth due to the increasing prevalence of CMV infections globally, particularly in immunocompromised populations such as organ transplant recipients and HIV patients. Moreover, the growing awareness of CMV's impact on newborns has contributed to the push for preventive vaccines. A few vaccines are in advanced clinical…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
Global Commercial Cooking Device Market Forecast 2018-2025 CMV Sharper Finish, Q …
Market study on Global Commercial Cooking Device 2018 Research Report presents a professional and complete analysis of Global Commercial Cooking Device Market on the current market situation.
Report provides a general overview of the Commercial Cooking Device industry 2018 including definitions, classifications, Commercial Cooking Device market analysis, a wide range of applications and Commercial Cooking Device industry chain structure. The 2018's report on Commercial Cooking Device industry offers the global…
Cytomegalovirus (CMV) Market: Size, Status, Opportunity Analysis and Forecasts t …
A new independent 162 page research with title 'Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as Atara Bio, Biotest AG, Helocyte, Merck & Co., Novartis, Shire, ViraCyte With n-number of tables and figures examining the Cytomegalovirus (CMV) Market, the research gives…
Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market Opportunity Analy …
Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can…
